Cargando…
Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression
Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is a dy...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204559/ https://www.ncbi.nlm.nih.gov/pubmed/37218871 http://dx.doi.org/10.3390/epigenomes7020010 |
_version_ | 1785045862705004544 |
---|---|
author | Srivastava, Rashmi Singh, Rubi Jauhari, Shaurya Lodhi, Niraj Srivastava, Rakesh |
author_facet | Srivastava, Rashmi Singh, Rubi Jauhari, Shaurya Lodhi, Niraj Srivastava, Rakesh |
author_sort | Srivastava, Rashmi |
collection | PubMed |
description | Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is a dynamically reversible and synchronously regulated process that orchestrates the three-dimensional epigenome, nuclear processes of transcription, DNA repair, cell cycle, and epigenetic functions, by adding or removing methylation groups to histones. Over the past few years, reversible histone methylation has become recognized as a crucial regulatory mechanism for the epigenome. With the development of numerous medications that target epigenetic regulators, epigenome-targeted therapy has been used in the treatment of malignancies and has shown meaningful therapeutic potential in preclinical and clinical trials. The present review focuses on the recent advances in our knowledge on the role of histone demethylases in tumor development and modulation, in emphasizing molecular mechanisms that control cancer cell progression. Finally, we emphasize current developments in the advent of new molecular inhibitors that target histone demethylases to regulate cancer progression. |
format | Online Article Text |
id | pubmed-10204559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102045592023-05-24 Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression Srivastava, Rashmi Singh, Rubi Jauhari, Shaurya Lodhi, Niraj Srivastava, Rakesh Epigenomes Review Epigenetic modifications are heritable, reversible changes in histones or the DNA that control gene functions, being exogenous to the genomic sequence itself. Human diseases, particularly cancer, are frequently connected to epigenetic dysregulations. One of them is histone methylation, which is a dynamically reversible and synchronously regulated process that orchestrates the three-dimensional epigenome, nuclear processes of transcription, DNA repair, cell cycle, and epigenetic functions, by adding or removing methylation groups to histones. Over the past few years, reversible histone methylation has become recognized as a crucial regulatory mechanism for the epigenome. With the development of numerous medications that target epigenetic regulators, epigenome-targeted therapy has been used in the treatment of malignancies and has shown meaningful therapeutic potential in preclinical and clinical trials. The present review focuses on the recent advances in our knowledge on the role of histone demethylases in tumor development and modulation, in emphasizing molecular mechanisms that control cancer cell progression. Finally, we emphasize current developments in the advent of new molecular inhibitors that target histone demethylases to regulate cancer progression. MDPI 2023-05-17 /pmc/articles/PMC10204559/ /pubmed/37218871 http://dx.doi.org/10.3390/epigenomes7020010 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Srivastava, Rashmi Singh, Rubi Jauhari, Shaurya Lodhi, Niraj Srivastava, Rakesh Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression |
title | Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression |
title_full | Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression |
title_fullStr | Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression |
title_full_unstemmed | Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression |
title_short | Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression |
title_sort | histone demethylase modulation: epigenetic strategy to combat cancer progression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204559/ https://www.ncbi.nlm.nih.gov/pubmed/37218871 http://dx.doi.org/10.3390/epigenomes7020010 |
work_keys_str_mv | AT srivastavarashmi histonedemethylasemodulationepigeneticstrategytocombatcancerprogression AT singhrubi histonedemethylasemodulationepigeneticstrategytocombatcancerprogression AT jauharishaurya histonedemethylasemodulationepigeneticstrategytocombatcancerprogression AT lodhiniraj histonedemethylasemodulationepigeneticstrategytocombatcancerprogression AT srivastavarakesh histonedemethylasemodulationepigeneticstrategytocombatcancerprogression |